| Literature DB >> 31241663 |
Maria Luiza do Val1, Fernanda Souza Menezes1, Henrique Tsuha Massaoka2, Valeska Tavares Scavarda3, Adriano Czapkowski4, Heitor Pons Leite1, Valdir Ambrósio Moises3, Sergio Aron Ajzen4, João Tomas de Abreu Carvalhaes1, José Osmar Medina Pestana5, Paulo Koch-Nogueira1.
Abstract
OBJECTIVES: To evaluate cardiovascular involvement in children and adolescents with End Stage Renal Disease (ESRD) and to characterize the main risk factors associated with this outcome.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31241663 PMCID: PMC6558996 DOI: 10.6061/clinics/2019/e859
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Demographic, anthropometric and clinical data of the sample according to the study group.
| Variable | Cases (n=69) | Controls (n=33) | |
|---|---|---|---|
| Mean Age in Years (SD) | 13.1 (4.6) | 13.0 (3.7) | 0.967 |
| Gender (Male/Female) | 39/30 | 17/16 | 0.635 |
| Mean Weight in kg (SD) | 38.4 (17.1) | 47.6 (14.3) | |
| Mean Height in cm (SD) | 141.7 (25.6) | 152.1 (18.5) | |
| H/A Z-Score (SD) | ‐1.6 (1.5) | ‐0.1 (0.9) | |
| BMI Z-Score (SD) | ‐0.6 (1.5) | 0.3 (0.8) | |
| Pubescent/Pre‐pubescent | 40/17 | 25/8 | 0.568 |
| Months Since Diagnosis (IQR) | 35 (13 to 72) | NA | NA |
| Months Undergoing Dialysis (IQR) | 14 (8 to 23) | NA | NA |
| Urinary Tract Malformation (n/total) | 26/69 | NA | NA |
| Systolic Blood Pressure (mmHg) | 122 (21) | 99 (11) | |
| Diastolic Blood Pressure (mmHg) | 76 (15) | 59 (9) |
SD‐Standard deviation of the mean, H/A‐Height/Age, BMI-Body mass index, NA-Not applicable, IQR‐Interquartile range of the median.
Figure 1Left ventricular Z-score according to study group.
Univariate and multivariate linear regression analysis of risk factors associated with left ventricular mass Z-score.
| Variable | Coefficient | CI | Coefficient | CI | ||
|---|---|---|---|---|---|---|
| Age | 0.084 | 0.013 to 0.155 | 0.083 | 0.009 to 0.157 | ||
| Gender | ‐0.334 | ‐1.008 to 0.339 | 0.328 | |||
| Body Mass Index (BMI) | ‐0.055 | ‐0.362 to 0.251 | 0.720 | |||
| Time Since Diagnosis | 0.000 | ‐0.008 to 0.008 | 0.991 | |||
| Dialysis Duration | 0.017 | ‐0.002 to 0.037 | 0.017 | 0.002 to 0.031 | ||
| Urinary Tract malformation | ‐0.755 | ‐1.562 to 0.050 | ||||
| Systolic Blood Pressure | 0.038 | 0.024 to 0.051 | 0.024 | 0.005 to 0.043 | ||
| Diastolic Blood Pressure | 0.045 | 0.025 to 0.065 | ||||
| Serum Hemoglobin (g/dL) | ‐0.214 | ‐0.416 to ‐0.013 | ‐0.204 | ‐0.379 to ‐0.028 | ||
| Serum Albumin (g/dL) | 0.310 | ‐0.255 to 0.876 | 0.277 | |||
| Serum Cholesterol (mg/dL) | ‐0.002 | ‐0.011 to 0.006 | 0.555 | |||
| Serum HDL (mg/dL) | ‐0.048 | ‐0.086 to ‐0.011 | ‐0.040 | ‐0.075 to ‐0.005 | ||
| Serum TG (mg/dL)) | 0.002 | ‐0.002 to 0.006 | 0.377 | |||
| Serum CRP (mg/dL) | 0.157 | ‐0.234 to 0.549 | 0.425 | |||
| Serum Uric Acid (mg/dL) | ‐0.064 | ‐0.289 to 0.160 | 0.570 | |||
| Serum Homoc (μmol/dL) | 0.011 | ‐0.033 to 0.568 | 0.613 | |||
| Serum Ionic Calcium(mg/dL) | ‐4.065 | ‐8.990 to 0.859 | 0.104 | |||
| Serum Phosphorus (mg/dL) | 0.166 | ‐0.101 to 0.434 | 0.219 | |||
| CaxP Product (mg/dL) | 0.010 | ‐0.019 to 0.040 | 0.475 | |||
| Serum PTH (pg/mL) | 0.000 | ‐0.000 to 0.001 | 0.145 | |||
| Serum FGF23 (pg/mL) | 0.000 | 0.000 to 0.000 | ||||
| Serum Vitamin D (ng/dL) | 0.011 | ‐0.021 to 0.043 | 0.500 | |||
| Vitamin D Use | 0.806 | ‐1.674 to 0.062 | ||||
| Use of Phosphate Binders | ‐0.130 | ‐1.106 to 0.845 | 0.790 |
Figure 2Carotid artery intima-medial thickness according to study group.
Univariate and multivariate analysis of risk factors associated with left carotid artery intima-medial thickness.
| Variable | Coefficient | CI | Coefficient | CI | ||
|---|---|---|---|---|---|---|
| Age | 0.005 | 0.001 to 0.010 | 0.003 | ‐0.001 to 0.008 | 0.122 | |
| Gender | ‐0.013 | ‐0.050 to 0.023 | 0.478 | |||
| Body Mass Index (BMI) | ‐0.008 | ‐0.021 to 0.003 | 0.168 | |||
| Time Since Diagnosis | ‐0.000 | ‐0.000 to 0.000 | 0.559 | |||
| Dialysis Duration | ‐0.000 | ‐0.001 to 0.000 | 0.733 | |||
| Urinary Tract Malformation | ‐0.021 | ‐0.066 to 0.024 | 0.364 | |||
| Systolic Blood Pressure | 0.001 | 0.000 to 0.002 | 0.001 | 0.000 to 0.002 | ||
| Diastolic Blood Pressure | 0.001 | 0.000 to 0.003 | 0.000 | ‐0.001 to 0.003 | 0.532 | |
| Serum Hemoglobin (g/dL) | ‐0.005 | ‐0.016 to 0.004 | 0.251 | |||
| Serum Albumin (g/dL) | 0.022 | ‐0.006 to 0.050 | 0.122 | |||
| Serum Cholesterol (mg/dL) | ‐0.000 | ‐0.000 to 0.000 | 0.176 | |||
| Serum HDL (mg/dL) | 0.001 | ‐0.000 to 0.003 | 0.181 | |||
| Serum TG (mg/dL) | ‐0.000 | ‐0.000 to 0.000 | 0.181 | |||
| Serum CRP (mg/dL) | ‐0.004 | ‐0.020 to 0.010 | 0.535 | |||
| Serum Uric Acid (mg/dL) | 0.001 | ‐0.013 to 0.015 | 0.881 | |||
| Serum Homoc (μmol/dL) | 0.002 | ‐0.001 to 0.006 | 0.251 | |||
| Serum Ionic Calcium (mg/dL) | 0.078 | ‐0.134 to 0.291 | 0.467 | |||
| Serum Phosphorus(mg/dL) | ‐0.006 | ‐0.023 to 0.010 | 0.450 | |||
| CaxP Product (mg/dL) | ‐0.000 | ‐0.002 to 0.001 | 0.649 | |||
| Serum PTH (pg/mL) | ‐0.000 | ‐0.000 to 0.000 | ‐0.500 | |||
| Serum FGF23(pg/mL) | ‐0.000 | ‐0.000 to 0.000 | 0.684 | |||
| Serum Vitamin D (ng/mL) | ‐0.000 | ‐0.001 to 0.001 | 0.924 | |||
| Vitamin D Use | ‐0.058 | ‐0.103 to ‐0.013 | ‐0.031 | ‐0.081 to 0.019 | 0.221 | |
| Use of Phosphate Binders | 0.024 | ‐0.025 to 0.074 | 0.333 |